Month: June 2012
Health Highlights: June 18, 2012
Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:
Infant Vaccination ‘Delays’ Triple in Oregon: Study
Some May Drink More After Weight-Loss Surgery: Study
America Awaits Supreme Court’s Ruling on Health Care Reform
MONDAY, June 18 (HealthDay News) — The U.S. Supreme Court will soon decide the fate of the most consequential piece of health legislation since the enactment of Medicare and Medicaid nearly a half-century ago.
Hotel Room Germs Abound on TV Remotes, Light Switches
FDA focuses on toxic side effects with Onyx drug
The toxic side effects of an experimental cancer drug from Onyx Pharmaceuticals may outweigh its benefits for patients with a type of blood cancer, federal health regulators said Monday.
Can too much exercise lead to heart attack?
When a high-profile athlete dies of a heart attack, couch potatoes every-where feel a little less guilty.
See all stories on this topic »
Obamacare was an exercise in bad judgment
| We pay our presidents for judgment, and President Barack Obama committed a colossal error of judgment in making health-care “reform” a centerpiece of his … See all stories on this topic » |
 Columbus Dispatch |
3D Systems Announces Exercise of Over-Allotment Option in Public …
ROCK HILL, S.C., Jun 18, 2012 (GlobeNewswire via COMTEX) — 3D Systems Corporation (NYSE:DDD) announced today that the underwriters for its recently …
See all stories on this topic »
A welcome let-up in health costs that may not last
FDA staff focus on Onyx cancer drug’s side effects
WASHINGTON (Reuters) – U.S. drug reviewers said the serious heart, lung and liver side effects of Onyx Pharmaceuticals Inc’s carfilzomib drug may outweigh the experimental drug’s benefits for patients with a type of blood cancer. The Food and Drug Administration staff said about 22 percent of people taking the drug during a key clinical trial responded to the medicine, and many had severe side effects, meaning carfilzomib may not be better than older treatments for multiple myeloma. …